Oramed Pharmaceuticals Inc. (ORMP)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Oramed Pharmaceuticals Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Oramed Pharmaceuticals Inc. (ORMP) has returned 27.97% so far this year and 70.42% over the past 12 months. Over the last ten years, ORMP has returned -6.63% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Apr 21, 2006, ORMP's average daily return is +0.14%, while the average monthly return is +1.68%. At this rate, your investment would double in approximately 3.5 years.

Historically, 47% of months were positive and 53% were negative. The best month was Jul 2022 with a return of +91.7%, while the worst month was Jan 2023 at -83.5%. The longest winning streak lasted 10 consecutive months, and the longest losing streak was 7 months.

On a daily basis, ORMP closed higher 42% of trading days. The best single day was Mar 24, 2015 with a return of +71.8%, while the worst single day was Jan 12, 2023 at -76.5%.

Oramed Pharmaceuticals Inc. has an annualized alpha of 34.28%, beta of 0.70, and R² of 0.02 versus S&P 500 Index. Calculated based on daily prices since April 24, 2006.

• This stock participated in 131.68% of S&P 500 Index downside but only 69.67% of its upside — more exposed to losses than it benefited from rallies.
• Beta of 0.70 may look defensive, but with R² of 0.02 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.02 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ORMP ranks 83 for risk / return — in the top 83% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Oramed Pharmaceuticals Inc. (ORMP) and compare them to a chosen benchmark (S&P 500 Index).

Oramed Pharmaceuticals Inc. provided a 7.35% dividend yield over the last twelve months, with an annual payout of $0.25 per share.

The table displays the monthly dividend distributions for Oramed Pharmaceuticals Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Oramed Pharmaceuticals Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Oramed Pharmaceuticals Inc. was 94.25%, occurring on Nov 1, 2023. The portfolio has not yet recovered.

The current Oramed Pharmaceuticals Inc. drawdown is 87.74%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Oramed Pharmaceuticals Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Oramed Pharmaceuticals Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.